Board of Directors
Acarix’s board of directors is the highest decision-making body after the general meeting of shareholders.
Philip Siberg
Chairman of the Board
Year of Entry: 2021
Born: 1973
Location: Sweden
Education: MSc in mechanical engineering and industrial economy from KTH Royal Institute of Technology, Stockholm, Sweden.
Previous engagements/experience: Philip Siberg has 20 years of experience as international CEO and Board member of public and unlisted companies in medical technology and life science. Philip has previously served as an external Chief Executive Officer of Coala Life AB and as Chairman of the Board of Annexin Pharmaceuticals AB.
Acarix holdings:
Shares: 440,000
Warrants: 500,000
Ken Nelson
Board Member
Year of Entry: 2024
Born: 1974
Location: USA
Education: Ken earned a B.A. in Economics from Vanderbilt University, and is a graduate of Phillips Exeter Academy,
Previous Engagements/Experience: Ken Nelson is a 20-year digital health, medical device, and remote patient monitoring executive and innovator with successful senior leadership experience ranging from a Fortune 500 company (Guidant/ Boston Scientific in Cardiac Rhythm Management) to a #1 market share leading medium-sized company (Biotelemetry, acquisition by Philips for $2.8 Billion announced in December ’20) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which was just acquired by HillRom/ Baxter (Bardy Diagnostics) in August 2021 for $450M+ after milestone payments.
Other Significant/Ongoing Assignments: Ken currently serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org ). In addition, he serves on the Boards of Directors of CardiaCare, HeartBeam (NASDAQ: BEAT), and Happitech. He is also on the advisory boards and/or planning committees, for SmartCardia, Bloomlife, AccurKardia, HeartX (MedAxiom/ ACC), HRX (Digital Health Summit of Heart Rhythm Society), and the American Heart Association.
Acarix holdings:
Employee Options: 1,000,000
Dr. Tony Das
Board Member
Year of entry: 2024
Born: 1964
Location: USA
Education: MIT Sloan School of Management Blockchain Technologies: Business Innovation and Application Course 2021
Stanford School of Business LEAD Corporate Innovation Program 2020
Texas Heart Institute- Interventional Cardiology and Endovascular Fellowship
Harvard Mass General- Internal Medicine Residency
Baylor College of Medicine- MD
Previous Engagements/Experience: Founder CEO, Connected Cardiovascular Care Associates (C3) First US Cardiology and Vascular Practice dedicated to a Digital First Approach for CV care using RPM services
System Medical Director, CV Strategic Development, Peripheral Vascular Interventions, Cardiac Innovation and Digital Health, Baylor Scott and White Healthcare, THHBP.
Other Significant Ongoing Assignments:
Stanford Business School: LEAD Corporate Innovation Program 2019
American College of Cardiology (ACC) Member CV Management Section
American College of Cardiology (ACC) Member Innovations Section and Digital Health and Wearables Working Group
Biostar Ventures Medical Venture Partner and Advisor
Sheltowee VC Fund Medical Advisor
Acarix holdings:
Shares: 2,000,600
Employee Options: 3,000,000
Marlou Janssen-Counotte
Board Member
Year of Entry: 2020
Born: 1965
Location: Netherlands
Education: Hotel Management at TIO.
Previous engagements/experience: Marlou Janssen-Counotte has more than 25 years of experience from the MedTech industry. She began her MedTech career at Medtronic and, in the past 20 years, has held senior executive roles as Vice President at St. Jude Medical, Vice President International Marketing & Sales at Biotronik and President and Board member at Biotronik Inc.
Other significant ongoing assignments: Head of EDP Solutions at Philips Medical Systems.
Acarix holdings:
Warrants: 500,000